Anti-Hu CD19 Alexa Fluor® 700

Anti-Hu CD19 Alexa Fluor<sup>®</sup> 700
Regulatory status
RUO
Antigen
CD19
Clone
4G7
Format
Alexa Fluor® 700
Reactivity
Human
Application
Excitation laser
red (633 nm)
Variant
100 tests
A7-663-T100
In stock
242.00 USD

25 tests
A7-663-T025
Delivery 1 week
121.00 USD
Variant
100 tests
A7-663-T100
In stock
242.00 USD

25 tests
A7-663-T025
Delivery 1 week
121.00 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody 4G7 recognizes an extracellular epitope of human CD19.
Workshop
HLDA: WS Code 2 B43
Application
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Reactivity
Human
Immunogen
Human CCL (chronic lymphocytic leukemia) cells
Preparation
Purified antibody is conjugated with Alexa Fluor® 700 NHS ester under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Licence note
Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registered trademarks of Life Technologies Corporation.
Licence label
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.
Other names
B4, Leu-12, CVID3
Antigen description
CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
Entrez Gene ID 930
UniProt ID P15391
A7-663_FC_Profil Značení
Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD19 (4G7) Alexa Fluor® 700 antibody (4 μl reagent / 100 μl of peripheral whole blood).
A7-663_FC_Histogram
Separation of human CD19 positive lymphocytes (red-filled) from neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD19 (4G7) Alexa Fluor® 700 antibody (4 μl reagent / 100 μl of peripheral whole blood).

General references:

Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep;56(9):3057-69.
PubMed
van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4;354(18):1901-12.
PubMed
Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15;99(2):584-9.
PubMed
Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15;162(12):7088-94.
PubMed

Product specific references:

Muench MO, Roncarolo MG, Namikawa R: Phenotypic and functional evidence for the expression of CD4 by hematopoietic stem cells isolated from human fetal liver. Blood. 1997 Feb 15;89(4):1364-75.
PubMed
Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T: Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol. 2000 Nov 15;165(10):5954-61.
PubMed
Dubois B, Massacrier C, Caux C: Selective attraction of naive and memory B cells by dendritic cells. J Leukoc Biol. 2001 Oct;70(4):633-41.
PubMed
Basu S, Lynne CM, Ruiz P, Aballa TC, Ferrell SM, Brackett NL: Cytofluorographic identification of activated T-cell subpopulations in the semen of men with spinal cord injuries. J Androl. 2002 Jul-Aug;23(4):551-6.
PubMed
Köller M, Zwölfer B, Steiner G, Smolen JS, Scheinecker C: Phenotypic and functional deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE) patients. Int Immunol. 2004 Nov;16(11):1595-604.
PubMed
Treusch M, Vonthein R, Baur M, Günaydin I, Koch S, Stübiger N, Eckstein AK, Peter HH, Ness T, Zierhut M, Kötter I: Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology (Oxford). 2004 Oct;43(10):1275-82.
PubMed
Porcellini S, Vallanti G, Nozza S, Poli G, Lazzarin A, Tambussi G, Siccardi AG, Grassi F: Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL-2 administration. AIDS. 2003 Jul 25;17(11):1621-30.
PubMed
Andersen P, Pedersen MW, Woetmann A, Villingshøj M, Stockhausen MT, Odum N, Poulsen HS: EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int J Cancer. 2008 Jan 15;122(2):342-9.
PubMed
Martino V, Tonelli R, Montemurro L, Franzoni M, Marino F, Fazzina R, Pession A: Down-regulation of MLL-AF9, MLL and MYC expression is not obligatory for monocyte-macrophage maturation in AML-M5 cell lines carrying t(9;11)(p22;q23). Oncol Rep. 2006 Jan;15(1):207-11.
PubMed
Leukocyte Typing II., Reinherz E.L. et al. (Eds.), Springer-Verlag (1985).
Mueller GA, Smith AM, Chapman MD, Rule GS, Benjamin DC: Hydrogen exchange nuclear magnetic resonance spectroscopy mapping of antibody epitopes on the house dust mite allergen Der p 2. J Biol Chem. 2001 Mar 23;276(12):9359-65.
PubMed
Smith AM, Benjamin DC, Hozic N, Derewenda U, Smith WA, Thomas WR, Gafvelin G, van Hage-Hamsten M, Chapman MD: The molecular basis of antigenic cross-reactivity between the group 2 mite allergens. J Allergy Clin Immunol. 2001 Jun;107(6):977-84.
PubMed
Variant
100 tests
A7-663-T100
In stock
242.00 USD

25 tests
A7-663-T025
Delivery 1 week
121.00 USD
Variant
100 tests
A7-663-T100
In stock
242.00 USD

25 tests
A7-663-T025
Delivery 1 week
121.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
ApplicationFC, FC(IC)
0.1 mg
231.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD